Hardman & Co issues research on Collagen Solutions

Hardman & Co issues research report on Collagen Solutions

Embedding technology: gross margins will drive value Collagen Solutions (COS) reports on a year of change with significant progress being made towards its short term goals of cash flow breakeven. The acquisition of SLB is delivering on its strategic intent. Evidence of cross selling products and services exists with sales approaching £1m. With clear evidence of meaningful gross margins (78%) and new customer wins, the anticipated higher sales volumes should begin to offset the c. £1.5m central overhead with cash flow breakeven anticipated in H2 2015/16. These margins, in turn, are expected to drive long term shareholder value.

Please click here for the full report:

http://www.hardmanandco.com/sites/default/files/research_papers/Collagen%20Solutions%20-%20FY%202015%20results_July%202015%20final.pdf

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.